• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微针药物洗脱球囊用于增强血管组织的药物输送。

Microneedle drug eluting balloon for enhanced drug delivery to vascular tissue.

机构信息

Department of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea; Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; California NanoSystems Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA.

Department of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea.

出版信息

J Control Release. 2020 May 10;321:174-183. doi: 10.1016/j.jconrel.2020.02.012. Epub 2020 Feb 6.

DOI:10.1016/j.jconrel.2020.02.012
PMID:32035908
Abstract

High rates of restenosis and neointimal formation have driven increasing interest in the application of drug eluting balloons (DEB) as counteractive measures for intraluminal drug delivery. The use of DEBs eliminates the need for stents so that serious side effects including in-stent restenosis and stent thrombosis can be avoided and long-term medication of anti-platelet agent is not needed. Despite their benefits, DEBs have poor drug delivery efficiency due to short balloon inflation times (30-60 s) that limit the passive drug diffusion from the balloon surface to the luminal lesion. To increase drug delivery efficiency, a microneedle DEB (MNDEB) was developed by a conformal transfer molding process using a thin polydimethylsiloxane mold bearing a negative array of MNs of 200 μm in height. A MN array composed of UV curable resin was formed onto the surface of DEB, and drugs were coated onto the structure. The mechanical properties of the MN array were investigated and MN penetration into luminal vasculature was confirmed in vivo. An increase in drug delivery efficiency compared to a standard DEB was demonstrated in an in vivo test in a rabbit aorta. Finally, the superior therapeutic efficacy of MNDEBs was evaluated using an atherosclerosis rabbit model.

摘要

高复发率和新生内膜形成率促使人们越来越关注药物洗脱球囊(DEB)在腔内药物输送中的应用,作为对抗措施。使用 DEB 可消除支架的需求,从而避免严重的副作用,包括支架内再狭窄和支架内血栓形成,并且不需要长期使用抗血小板药物。尽管具有这些优势,但 DEB 的药物输送效率较差,因为球囊充气时间短(30-60 秒),限制了药物从球囊表面向管腔病变的被动扩散。为了提高药物输送效率,采用保形转移模塑工艺,使用带有负性微针阵列的薄聚二甲基硅氧烷模具(高度为 200μm),开发了微针 DEB(MNDEB)。在 DEB 的表面形成由紫外光固化树脂组成的微针阵列,并将药物涂覆在该结构上。研究了微针阵列的机械性能,并在体内证实了微针穿透管腔血管。在兔主动脉的体内试验中,与标准 DEB 相比,显示出药物输送效率的提高。最后,使用动脉粥样硬化兔模型评估了 MNDEB 的优越治疗效果。

相似文献

1
Microneedle drug eluting balloon for enhanced drug delivery to vascular tissue.微针药物洗脱球囊用于增强血管组织的药物输送。
J Control Release. 2020 May 10;321:174-183. doi: 10.1016/j.jconrel.2020.02.012. Epub 2020 Feb 6.
2
Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.载药支架与药物球囊治疗金属裸支架内再狭窄的长期疗效:RIBS V 临床试验 3 年随访结果。
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-1255. doi: 10.1016/j.jcin.2016.03.037. Epub 2016 Jun 20.
3
In-stent restenosis: the gold standard has changed.支架内再狭窄:金标准已改变。
EuroIntervention. 2011 May;7 Suppl K:K43-6. doi: 10.4244/EIJV7SKA7.
4
Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.药物洗脱支架再狭窄的治疗:一项回顾性观察研究中药物洗脱球囊与第二代药物洗脱支架的比较
Catheter Cardiovasc Interv. 2016 Oct;88(4):522-528. doi: 10.1002/ccd.26368. Epub 2015 Dec 30.
5
Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.光学相干断层扫描(OCT)在经皮冠状动脉介入治疗(PCI)中的支架内再狭窄(ISR):SEDUCE 研究(药物洗脱球囊在冠状动脉再狭窄中的安全性和疗效)的原理和设计。
EuroIntervention. 2011 May;7 Suppl K:K100-5. doi: 10.4244/EIJV7SKA17.
6
Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.紫杉醇洗脱球囊后扩张与依维莫司洗脱支架治疗裸金属支架:使用光学相干断层成像术在 6 个月随访时的前瞻性随机研究。
Circ Cardiovasc Interv. 2014 Dec;7(6):760-7. doi: 10.1161/CIRCINTERVENTIONS.113.001146. Epub 2014 Nov 4.
7
Intravascular imaging analysis of a drug-eluting balloon followed by a bare metal stent compared to a drug-eluting stent for treatment of de novo lesions.药物洗脱球囊治疗后行血管内影像学分析与药物洗脱支架治疗初发病变的比较。
Korean J Intern Med. 2019 Jul;34(4):819-829. doi: 10.3904/kjim.2017.378. Epub 2018 Jul 4.
8
Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial.糖尿病和非糖尿病患者小冠状动脉中紫杉醇药物洗脱球囊与紫杉醇洗脱支架的比较——BELLO(球囊洗脱与晚期丢失优化)试验结果
Cardiovasc Revasc Med. 2017 Jan-Feb;18(1):4-9. doi: 10.1016/j.carrev.2016.12.008. Epub 2016 Dec 15.
9
Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.紫杉醇洗脱球囊与标准球囊血管成形术治疗股浅动脉和腘动脉支架内再狭窄:PACUBA 试验 1 年结果。
JACC Cardiovasc Interv. 2016 Jul 11;9(13):1386-92. doi: 10.1016/j.jcin.2016.04.012.
10
Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis.药物涂层球囊血管成形术治疗支架内再狭窄中优化操作相关因素的影响。
JACC Cardiovasc Interv. 2018 May 28;11(10):969-978. doi: 10.1016/j.jcin.2018.02.002.

引用本文的文献

1
From to : Diverse applications of kirigami technology in medical devices.从 到 :折纸技术在医疗设备中的多样应用。
Mater Today Bio. 2025 Jun 11;33:101961. doi: 10.1016/j.mtbio.2025.101961. eCollection 2025 Aug.
2
Flexible porous microneedle array for bioelectric skin patch.用于生物电皮肤贴片的柔性多孔微针阵列
Biomed Microdevices. 2025 May 10;27(2):21. doi: 10.1007/s10544-025-00749-y.
3
Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.经皮冠状动脉介入治疗中的药物涂层球囊:现有证据与新希望
Cardiol J. 2025;32(3):308-320. doi: 10.5603/cj.101393. Epub 2025 Apr 14.
4
Recent advances in microneedles for enhanced functional angiogenesis and vascular drug delivery.用于增强功能性血管生成和血管药物递送的微针的最新进展。
Ther Deliv. 2025 Apr;16(4):393-406. doi: 10.1080/20415990.2025.2468148. Epub 2025 Feb 25.
5
Bioengineering Strategies for Treating Neointimal Hyperplasia in Peripheral Vasculature: Innovations and Challenges.治疗外周血管新生内膜增生的生物工程策略:创新与挑战
Adv Healthc Mater. 2025 Mar;14(7):e2401056. doi: 10.1002/adhm.202401056. Epub 2025 Jan 31.
6
Everolimus-encapsulation in Pluronic P123 self-assembled micelles as drug delivery systems for drug-coated balloons.依维莫司包裹于普朗尼克P123自组装胶束中作为药物涂层球囊的药物递送系统。
Int J Pharm X. 2024 Jan 10;7:100230. doi: 10.1016/j.ijpx.2024.100230. eCollection 2024 Jun.
7
Advances in Polysaccharide-Based Microneedle Systems for the Treatment of Ocular Diseases.用于治疗眼部疾病的基于多糖的微针系统的进展
Nanomicro Lett. 2024 Aug 13;16(1):268. doi: 10.1007/s40820-024-01477-3.
8
Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis.纳米颗粒靶向递送至血管用于治疗动脉粥样硬化
Biomedicines. 2024 Jul 6;12(7):1504. doi: 10.3390/biomedicines12071504.
9
Research progress of drug eluting balloon in arterial circulatory system.药物洗脱球囊在动脉循环系统中的研究进展
Front Cardiovasc Med. 2024 Mar 20;11:1287852. doi: 10.3389/fcvm.2024.1287852. eCollection 2024.
10
Plaque heterogeneity and the spatial distributions of its components dictate drug-coated balloon therapy.斑块异质性及其成分的空间分布决定了药物涂层球囊治疗。
Sci Rep. 2024 Feb 22;14(1):4412. doi: 10.1038/s41598-024-54756-9.